What is hyaluronic acid?
Hyaluronic acid (HA) is a high-molecular-weight glycosaminoglycan built from repeating disaccharide units of glucuronic acid and N-acetylglucosamine. This page summarises laboratory and clinical research on HA and HA-con
Hyaluronic acid (HA), also called hyaluronan, is a non-sulfated glycosaminoglycan composed of repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine. It is a linear polysaccharide of the extracellular matrix and is used in research as a hydrogel base, a delivery excipient, and a formulation component. The evidence block for this page does not specify a single molecular weight, sequence, or CAS number for HA; studies describe HA-based materials and HA-containing formulas without reporting those identifiers uniformly.
The biological and formulation work summarised here centres on HA as a substrate for oxidative chain scission, as a component of hydrogels and dermal fillers, and as a targeting or coating ligand in nanoparticle systems; where a receptor or pathway is named, it is the NF-κB pathway in chondrocytes, the NLRP3–TXNIP–iNOS axis in a rat osteoarthritis model, and the SPI1/miR-616-5p axis in non-small cell lung cancer cells.
Research Studies
Hyaluronic acid and oxidative chain scission in hydrogel wound-healing materials
HA-based hydrogels are widely used as wound-healing materials and topical delivery systems because of their biocompatibility, water retention, and ability to promote cell migration. However, HA is prone to oxidative chain scission, which reduces molecular weight and compromises formulation stability and functional performance. One study evaluated ergothioneine (EGT) as a candidate antioxidant stabilizing excipient in a model HA-based wound-healing material. CCK-8 assays assessed EGT biocompatibility in L929 mouse fibroblasts after 24 h of exposure, and a stress-screening framework including Fenton oxidation and high-temperature/high-humidity conditions was applied [2]. This work is in vitro and uses a mouse fibroblast line; it does not establish performance in human wound care.
Ectoine and IL-1β-induced NF-κB signalling in chondrocytes and a rat osteoarthritis model
Osteoarthritis is a degenerative joint disease characterised by inflammation and cartilage destruction, partly mediated by interleukin (IL)-1β-induced NF-κB activation. Ectoine, a natural osmoprotectant, was investigated for its effects on NF-κB signalling in osteoarthritis. Primary rat chondrocytes were pretreated with ectoine (0–3.0% w/v) and then stimulated with IL-1β (10 ng/mL); cell viability was evaluated, and RT-qPCR and Western blot analyses were performed. The study reported that ectoine attenuated IL-1β-induced inflammation in chondrocytes by suppressing NF-κB activation and mitigated osteoarthritis progression in a rat model [3]. The chondrocyte experiments are in vitro and the osteoarthritis model is in rats; no human dosing or clinical outcome is reported.
Niacinamide-enriched cross-linked hyaluronic acid dermal filler and collagen stimulation
Biological skin aging involves structural changes including flattening of the epidermal–dermal junction and reduced collagen types I and III. A study evaluated the biostimulatory, antimicrobial, anti-inflammatory, and safety profiles of a niacinamide-enriched cross-linked hyaluronic acid dermal filler (HAR) compared to untreated controls and Belotero Balance® [4]. The evidence block does not report the numerical results of that comparison, so no effect size is stated here. This is a dermal filler study; it is not a study of oral hyaluronic acid.
REJENERA and the NLRP3–TXNIP–iNOS axis in a rat osteoarthritis model
REJENERA© is a multi-component nutraceutical formula containing olive leaf bioflavonoids (ZeyEX©, quercetin and luteolin), S-allylcysteine, palmitoylethanolamide, L-proline, hyaluronic acid and boron. A study compared REJENERA with ZeyEX, NPROC© (collagen-rich eggshell membrane combined with olive leaf extract), and ibuprofen in a rat osteoarthritis model established by intra-articular injection of monosodium iodoacetate (MIA; 3 mg) into the right knee joint [5]. The work reports effects on the NLRP3–TXNIP–iNOS axis and inflammation. Because the formula contains multiple components, the study does not isolate the contribution of hyaluronic acid, and the model is a rat model.
Hyaluronic acid in a chlorhexidine mouthwash and human gingival fibroblasts
A prospective in vitro study is evaluating the effects of two chlorhexidine-based mouthwash formulations on the survival and function of human gingival fibroblasts (hGFs). Gingival fibroblasts obtained from discarded gingival tissue collected during routine dental procedures are cultured and exposed to different concentrations of a conventional 0.2% chlorhexidine mouthwash and a 0.2% chlorhexidine mouthwash supplemented with N-acetylcysteine (NAC) and hyaluronic acid (HA). Cell viability, apoptosis, migration, and gene expression are assessed at multiple time points using Trypan Blue exclusion assay, fluorescence-activated cell sorting (FACS), scratch assay, and quantitative RT-PCR [6]. This is an in vitro study of a mouthwash formulation; it does not test oral ingestion of HA.
Oral EGCG, folic acid, vitamin B12 and hyaluronic acid in persistent HPV infection
An interventional, single-centre, open-label randomised clinical study is evaluating an oral dietary supplement (Pervistop®) in women with persistent human papillomavirus (HPV) infection. The supplement combines epigallocatechin gallate (EGCG), folic acid (FA), vitamin B12 (B12), and hyaluronic acid (HA). The primary objective is to describe the effect of this association on HPV DNA integration into the host genome by measuring the clearance rate of viral oncoproteins E6 and E7. A total of 42 women aged 25 or older with persistent HPV infection and low-grade cervical lesions are randomised 1:1 into two groups [7]. The population is adult women with persistent HPV infection; the intervention is a four-component supplement, so the study does not isolate hyaluronic acid.
Hyaluronic acid and folic acid-modified mesoporous silica nanoparticles delivering sulforaphane in NSCLC
Sulforaphane (SF) suppresses non-small cell lung cancer (NSCLC) metastasis by modulating miR-616-5p, which is transcriptionally upregulated by the oncogenic transcription factor SPI1. In this study, SPI1 expression in NSCLC tissues positively correlated with miR-616-5p levels, and SPI1 transcriptionally regulated miR-616-5p to promote NSCLC cell invasion and migration. SF was found to bind SPI1 directly, inhibiting its activity and downregulating miR-616-5p expression, thereby attenuating NSCLC metastasis. Because the poor stability of SF limits its clinical application, the authors developed a delivery system using hyaluronic acid and folic acid-modified mesoporous silica nanoparticles [8]. This is a preclinical nanoparticle delivery study in NSCLC models; it does not report human outcomes.
Oral hyaluronic acid drink and knee pain
A clinical trial is evaluating the effect of an A+HA premium oral hyaluronic acid drink on relieving knee pain [1]. The evidence block provides the objective of the trial but does not report enrolled population size, dose, duration, or results. No efficacy claim can be made from this record alone.
Comparison of HA-containing research contexts
| Study context | HA role | Model or population | Reported focus |
|---|---|---|---|
| Ergothioneine stabilisation of HA hydrogel [2] | Hydrogel base | L929 mouse fibroblasts; in vitro stress screening | Oxidative chain scission and formulation stability |
| Ectoine in osteoarthritis [3] | Not the test article | Primary rat chondrocytes; rat OA model | IL-1β-induced NF-κB signalling |
| Niacinamide-enriched HA dermal filler [4] | Cross-linked filler matrix | Dermal filler comparison | Biostimulation, antimicrobial and anti-inflammatory profile |
| REJENERA formula [5] | One of several components | Rat OA model (MIA injection) | NLRP3–TXNIP–iNOS axis and inflammation |
| Chlorhexidine mouthwash with HA [6] | Mouthwash additive | Human gingival fibroblasts; in vitro | Viability, apoptosis, migration, gene expression |
| Pervistop® oral supplement [7] | One of four components | Women with persistent HPV infection | HPV DNA integration; E6/E7 clearance |
| HA/folate mesoporous silica nanoparticles [8] | Targeting/coating ligand | NSCLC models | SPI1/miR-616-5p axis |
| A+HA oral drink [1] | Oral drink component | Knee pain trial | Knee pain relief (objective only) |
If you are reading this for personal health reasons
The materials described on this page are sold for laboratory research use only. We do not provide dosing, medical guidance, or recommendations for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] A+HA Premium Oral Hyaluronic Acid Drink Functional Evaluation Trial for Delaying Joint Pain — https://clinicaltrials.gov/study/NCT07800676
- [2] Effect of Ergothioneine on the Stability of Hyaluronic Acid-Based Wound-Healing Materials — https://europepmc.org/article/PMC/PMC13517268
- [3] Ectoine Inhibits IL-1β-Induced Inflammation by Suppressing the NF-κB Pathway in Chondrocytes and Alleviates Osteoarthritis in a Rat Model — https://europepmc.org/article/PMC/PMC13510090
- [4] A smarter dermal filler: Antimicrobial protection and collagen stimulation with niacinamide — https://pubmed.ncbi.nlm.nih.gov/42437592/
- [5] REJENERA©, a multi-component bioflavonoid-based formula, alleviates osteoarthritis and provides chondroprotection by regulating the NLRP3-TXNIP-iNOS axis and inflammation: a comparative study with olive leaf nutraceuticals and ibuprofen — https://europepmc.org/article/PMC/PMC13525066
- [6] Effects of Chlorhexidine on Human Gingival Fibroblasts — https://clinicaltrials.gov/study/NCT07669636
- [7] Effect of EGCG, Folic Acid, Vitamin B12 and Hyaluronic Acid on HPV DNA Integration — https://clinicaltrials.gov/study/NCT07697196
- [8] Hyaluronic acid and folic acid-modified mesoporous silica nanoparticles delivering sulforaphane suppress NSCLC via SPI1/miR-616-5p axis — https://europepmc.org/article/PMC/PMC13276326